The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Sensus Healthcare
- The Trade: Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Samuel O'Rear acquired a total 20,000 shares an average price of $2.99. To acquire these shares, it cost around $59.85 thousand. The company's President and General Counsel also bought the company's shares.
- What's Happening: Sensus Healthcare reported worse-than-expected Q1 EPS and sales results.
- What Sensus Healthcare Does: Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system.
Esperion Therapeutics
- The Trade: Esperion Therapeutics, Inc. (NASDAQ:ESPR) President and CEO Sheldon L Koenig acquired a total of 20,000 shares at an average price of $1.26. The insider spent around $25.19 thousand to buy those shares.
- What's Happening: Esperion Therapeutics posted a wider-than-expected quarterly loss.
- What Esperion Therapeutics Does: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol.
TCR2 Therapeutics
- The Trade: TCR2 Therapeutics Inc. (NASDAQ:TCRR) 10% owner Tang Capital Partners LP acquired a total of 83,988 shares at an average price of $1.95. To acquire these shares, it cost around $163.78 thousand.
- What's Happening: TCR2 Therapeutics posted a wider Q4 loss.
- What TCR2 Therapeutics Does: TCR2 Therapeutics Inc is a clinical-stage cell therapy company.
Check This Out: Investor Sentiment Declines Slightly Following Inflation Data
Don't forget to check out our premarket coverage here